Objective

To determine the optimal dose of caffeine citrate for very preterm infants experiencing apnoea of prematurity (breathing problems).

Who will be eligible?

Very preterm infants (babies born less than 32 weeks gestation) who meet the eligibility criteria and are receiving care at a hospital taking part in this trial.

Why is this important?

Apnoea of prematurity is when a baby born preterm stops breathing intermittently. It is common in preterm babies and occurs in almost all babies born at less than 28 weeks gestation.

Caffeine is routinely given to preterm babies who experience apnoea of prematurity. Caffeine has been shown to reduce both the number of times a baby stops breathing, and the number of babies who need additional help to breathe. This is important as it may also help to reduce the risk of other complications after birth and in the future.

Why are we doing this study?

The optimal dose of caffeine is unknown, and caffeine dosing practices vary in Australia, Aotearoa New Zealand and worldwide.

BabyCCINO will assess three common caffeine doses and dosing regimens that are given to babies born preterm in Australia and Aotearoa New Zealand, to reduce uncertainty and understand which dose is best for babies who experience apnoea of prematurity.

‍

Funder: NHMRC and MRFF

Ethics Reference: [Pending]

Trial Registration: [Pending]

Lead Investigators: Professor Brett Manley and Associate Professor Chris McKinlay

‍